About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00528242

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.

Lead sponsor: Response Pharmaceuticals•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Response Pharmaceuticals

1. Number and cumulative duration of Raynaud's attacks. 2. Adverse events and changes in vital signs. 3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to Cmax (tmax), and accumulation ratio

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•male and female ages 18 and 65 y.o.
•BMI Body weight within a body mass index range of 17 - 30 kg/m2 (inclusive).

Exclusion Criteria

•Hypersensitivity to the active substance of SLx-2101or to any of the excipients.
•Past or present disease that is judged by the Investigator to have the potential to interfere with the study procedures, compromise safety, or affect the pharmacokinetic and pharmacodynamic evaluations

Related studies

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)

NCT02396238 · Scleroderma, Systemic Sclerosis, and more

COMPLETEDPhase 2

PF-00489791 For The Treatment Of Raynaud's

NCT01090492 · Raynaud's Disease, Peripheral Vascular Disease

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

NCT02683408 · Raynaud's Disease

Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.

NCT02615964 · Raynaud's Disease

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304 · Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 18, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment17

Start dateJun 2007

Last updatedNov 18, 2023

Condition

Raynaud's Disease

Locations shown

University des Saarlandes

Homburg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions